SuperworthCytek Biosciences shares outstanding CTKB
Diluted shares outstanding, averaged over each quarter, from 2020.
- Latest quarter, to Jun 30, 2026
- 129.5M
- On a year earlier
- +2.0%
- more shares
Cytek Biosciences had 129.5M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 2.0% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 128.2M | −1% |
| FY2024 | 129.1M | −3% |
| FY2023 | 133.6M | −4% |
| FY2022 | 139.1M | −0% |
| FY2021 | 139.3M | +266% |
| FY2020 | 38.1M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 129.5M | +2% | |
| Q1 FY26 | 128.7M | +0% | |
| Q4 FY25 | 128.2M | −1% | |
| Q3 FY25 | 127.5M | −4% | |
| Q2 FY25 | 126.9M | −3% | |
| Q1 FY25 | 128.3M | −2% | |
| Q4 FY24 | 129.1M | −3% | |
| Q3 FY24 | 132.8M | −2% | |
| Q2 FY24 | 131.4M | −3% | |
| Q1 FY24 | 130.9M | −3% | |
| Q4 FY23 | 133.6M | −4% | |
| Q3 FY23 | 136.2M | −2% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Cytek Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.